Harwin Peter Evan's Form 4 filing
Apogee Therapeutics, Inc. (APGE) · filed Sep 3, 2026
- Accession no.
- 0001104659-26-105119
- Filed
- Sep 3, 2026, 5:30 PM ET
- Trade date
- Sep 3, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 5 derivative transactions. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director |
| Fairmount Funds Management LLCCIK 0001802528 | Director |
| Kiselak TomasCIK 0001830177 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −340,855 | –F1 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −51,166 | –F1 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −51,166 | –F1 | – | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −6,743,321 | –F1 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −47,758 | –F5 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −10,370 | –F5 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −14,461 | –F5 | – | 0 | Indirect | |
| Sep 3, 2026 | Common Stock | DReturned to the companyDisposed | −7,657 | –F5 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the "Merger Agreement"), in exchange for a cash payment equal to $135.11 per Share without interest (the "Merger Consideration").
Referenced by the price of 3 transactions in Table I and 1 transaction in Table II.
- F5
Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option.
Referenced by the price of 4 transactions in Table II.
Remarks
Fairmount and Fairmount Healthcare Fund II LP may each have been deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak served on the board of directors of the Issuer and is also a Managing Member of Fairmount.